

Medical Coverage Policy | Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)



EFFECTIVE DATE: 01|01|2024

POLICY LAST REVIEWED: 01|07|2026

OVERVIEW

Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in peripheral blood, referred to as “liquid biopsy,” have several potential uses for guiding therapeutic decisions in patients with cancer or being screened for cancer.

This policy does not address the use of blood-based testing (liquid biopsy) to select targeted treatment for breast cancer, metastatic colorectal cancer, non-small cell lung cancer, melanoma/glioma, ovarian cancer, pancreatic cancer, and prostate cancer, the use of liquid biopsy to select immune checkpoint inhibitor therapy, tumor-Informed circulating tumor DNA testing for cancer management, comprehensive genomic profiling for selecting targeted cancer therapies, the use of blood-based testing for detection or risk assessment of prostate cancer; or the use of AR-V7 circulating tumor cells for metastatic prostate cancer.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

Note: Laboratories are not allowed to obtain clinical authorization or participate in the authorization process on behalf of the ordering physician. Only the ordering physician shall be involved in the authorization, appeal or other administrative processes related to prior authorization/medical necessity.

In no circumstance shall a laboratory or a physician/provider use a representative of a laboratory or anyone with a relationship to a laboratory and/or a third party to obtain authorization on behalf of the ordering physician, to facilitate any portion of the authorization process or any subsequent appeal of a claim where the authorization process was not followed and/or a denial for clinical appropriateness was issued, including any element of the preparation of necessary documentation of clinical appropriateness. If a laboratory or a third party is found to be supporting any portion of the authorization process, BCBSRI will deem the action a violation of this policy and severe action will be taken up to and including termination from the BCBSRI provider network. If a laboratory provides a laboratory service that has not been authorized, the service will be denied as the financial liability of the participating laboratory and may not be billed to the member.

POLICY STATEMENT

Medicare Advantage Plans

The use of circulating tumor DNA and/or circulating tumor cells is not covered for all indications as the evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial Products

The use of circulating tumor DNA and/or circulating tumor cells is considered not medically necessary for all indications as the evidence is insufficient to determine the effects of the technology on health outcomes.

Some genetic testing services are not covered and a contract exclusion for any self-funded group that has excluded the expanded coverage of biomarker testing related to the state mandate, R.I.G.L. §27-19-81 described in the Biomarker Testing Mandate policy. For these groups, a list of which genetic testing services are covered with prior authorization, are not medically necessary or are not covered because they are a

contract exclusion can be found in the Coding section of the Genetic Testing Services or Proprietary Laboratory Analyses policies. Please refer to the appropriate Benefit Booklet to determine whether the member's plan has customized benefit coverage. Please refer to the list of Related Policies for more information.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate section of the Benefit Booklet, Evidence of Coverage or Subscriber Agreement for services not medically necessary.

BACKGROUND

Liquid biopsy refers to analysis of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) as methods of noninvasively characterizing tumors and tumor genome from the peripheral blood.

Circulating Tumor DNA

Normal and tumor cells release small fragments of DNA into the blood, which is referred to as cell-free DNA. Cell-free DNA from nonmalignant cells is released by apoptosis. Most cell-free tumor DNA is derived from apoptotic and/or necrotic tumor cells, either from the primary tumor, metastases, or CTCs. Unlike apoptosis, necrosis is considered a pathologic process, and generates larger DNA fragments due to an incomplete and random digestion of genomic DNA. The length or integrity of the circulating DNA can potentially distinguish between apoptotic and necrotic origin. Circulating tumor DNA can be used for genomic characterization of the tumor.

Circulating Tumor Cells

Intact CTCs are released from a primary tumor and/or a metastatic site into the bloodstream. The half-life of a CTC in the bloodstream is short (1-2 hours), and CTCs are cleared through extravasation into secondary organs. Most assays detect CTCs through the use of surface epithelial markers such as EpCAM and cytokeratins. The primary reason for detecting CTCs is prognostic, through quantification of circulating levels.

Detecting Circulating Tumor DNA and Circulating Tumor Cells

Detection of ctDNA is challenging because ctDNA is diluted by nonmalignant circulating DNA and usually represents a small fraction (<1%) of total cell free DNA. Therefore, more sensitive methods than the standard sequencing approaches (e.g., Sanger sequencing) are needed.

Highly sensitive and specific methods have been developed to detect ctDNA, for both single nucleotide mutations e.g. BEAMing [which combines emulsion polymerase chain reaction with magnetic beads and flow cytometry] and digital polymerase chain reaction and copy-number changes. Digital genomic technologies allow for enumeration of rare mutant variants in complex mixtures of DNA.

Approaches to detecting ctDNA can be considered targeted, which includes the analysis of known genetic mutations from the primary tumor in a small set of frequently occurring driver mutations, which can impact therapy decisions, or untargeted without knowledge of specific mutations present in the primary tumor, and include array comparative genomic hybridization, next-generation sequencing, and whole exome and genome sequencing.

CTC assays usually start with an enrichment step that increases the concentration of CTCs, either on the basis of biologic properties (expression of protein markers) or physical properties (size, density, electric charge). CTCs can then be detected using immunologic, molecular, or functional assays.

For individuals who have advanced cancer who receive testing of CTCs to select targeted treatment, the evidence includes observational studies. The relevant outcomes are overall survival, progression-free survival, recurrence-free survival, disease-specific survival, test accuracy and validity, morbid events, and medication use. Given the breadth of methodologies available to assess CTCs, the clinical validity of each commercially

available test must be established independently, and these data are lacking. Published studies reporting clinical outcomes and/or clinical utility are lacking. The uncertainties concerning clinical validity and clinical utility preclude conclusions about whether the use of CTCs can replace variant analysis of tissue. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have cancer who receive testing of ctDNA to monitor treatment response, the evidence includes randomized clinical trials, systematic reviews with meta-analysis, and observational studies. Relevant outcomes are overall survival, progression-free survival, recurrence-free survival, disease-specific survival, test accuracy and validity, morbid events, and medication use. Numerous randomized clinical trials and systematic reviews identified an association with the detection of ctDNA or the kinetics of ctDNA and worse clinical outcomes for individuals with cancer, thus illustrating the clinical validity of testing for ctDNA. However, studies reporting clinical utility are lacking. Further studies are needed to establish a standardized definition for ctDNA molecular response and to illustrate how ctDNA testing can lead to different treatment regimens for cancer management. The uncertainties concerning clinical validity and clinical utility preclude conclusions about whether the use of ctDNA should be used to monitor treatment response. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have cancer who receive testing of CTCs to monitor treatment response, the evidence includes a randomized controlled trial, observational studies, and systematic reviews of observational studies. Relevant outcomes are overall survival, progression-free survival, recurrence-free survival, disease-specific survival, test accuracy and validity, morbid events, and medication use. Given the breadth of methodologies available to assess CTCs, the clinical validity of each commercially available test must be established independently, and these data are lacking. The available randomized controlled trial found no effect on overall survival when patients with persistently increased CTC levels after first-line chemotherapy were switched to an alternative cytotoxic therapy. Other studies reporting clinical outcomes and/or clinical utility are lacking. The uncertainties concerning clinical validity and clinical utility preclude conclusions about whether the use of CTCs should be used to monitor treatment response. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have received curative treatment for cancer who receive testing of ctDNA to predict risk of relapse, the evidence includes randomized clinical trials, systematic reviews with meta-analysis, and observational studies. Relevant outcomes are overall survival, progression-free survival, recurrence-free survival, disease-specific survival, test accuracy and validity, morbid events, and medication use. Numerous randomized clinical trials and systematic reviews identified an association with the detection of ctDNA or the kinetics of ctDNA and worse clinical outcomes for individuals with cancer, thus illustrating the clinical validity of testing for ctDNA. However, there were no studies assessing clinical utility. Further studies are needed to distinguish the timing to assess ctDNA to accurately prognosticate the clinical outcomes for individuals with cancer and establish thresholds that lead to meaningful predictions for clinical outcomes. The uncertainties concerning clinical validity and clinical utility preclude conclusions about whether the use of ctDNA should be used to predict relapse response. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have received curative treatment for cancer who receive testing of CTCs to predict risk of relapse, the evidence includes observational studies. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, morbid events, and medication use. Given the breadth of methodologies available to assess CTCs, the clinical validity of each commercially available test must be established independently, and these data are lacking. Published studies reporting clinical outcomes and/or clinical utility are lacking. The uncertainties concerning clinical validity and clinical utility preclude conclusions about whether the use of CTCs should be used to predict relapse response. The evidence is insufficient to determine the effects of the technology on health outcomes.

CODING

The following codes are not covered for Medicare Advantage Plans and not medically necessary for Commercial products:

- 86152** Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood)
- 86153** Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood); physician interpretation and report, when required

This CPT code can be used for FirstSightCRC™ (CellMax Life)

0091U Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm, for the presence of adenoma or cancer, reported as a positive or negative result

RELATED POLICIES

Biomarker Testing Mandate

Genetic Testing Services

Proprietary Laboratory Analyses (PLA)

PUBLISHED

Provider Update, January/March 2026

Provider Update, November 2024

Provider Update, January/November 2023

Provider Update, May 2021

Provider Update, June 2019

REFERENCES

1. Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD): Next Generation Sequencing (90.2)
2. Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD): MolDX: Molecular Diagnostic Tests (MDT) (L35160)
3. Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD) article: Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (A57526)
4. Alix-Panabières C, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. *Cancer Discov.* May 2016; 6(5): 479-91. PMID 26969689
5. Food & Drug Administration. 2025. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools>. Accessed October 27, 2025
6. Merker JD, Oxnard GR, Compton C, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. *J Clin Oncol.* Jun 01 2018; 36(16): 1631-1641. PMID 29504847
7. Pascual J, Attard G, Bidard FC, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. *Ann Oncol.* Aug 2022; 33(8): 750-768. PMID 35809752
8. Ruiz-Vico M, Wetterskog D, Orlando F, et al. Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial. *Eur Urol Oncol.* Feb 2025; 8(1): 135-144. PMID 39261236
9. LaPelusa M, Qiao W, Iorgulescu B, et al. Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors. *Nat Commun.* May 15 2025; 16(1): 4514. PMID 40374594
10. Rodrigues M, Ramtohul T, Rampanou A, et al. Prospective assessment of circulating tumor DNA inpatients with metastatic uveal melanoma treated with tebentafusp. *Nat Commun.* Oct 14 2024; 15(1):8851. PMID 39402032
11. Knutson TP, Luo B, Kobilka A, et al. AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients. *Nat Commun.* Dec 11 2024; 15(1): 10648. PMID 39663356
12. Han JY, Ahn MJ, Lee KH, et al. Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study. *BMC Med.* Oct 08 2024; 22(1): 428. PMID 39379931

13. Herbst RS, John T, Grohé C, et al. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIa non-small-cell lung cancer. *Nat Med.* Jun 2025; 31(6): 1958-1968. PMID 40097663
14. Syeda MM, Long GV, Garrett J, et al. Clinical validation of droplet digital PCR assays in detecting BRAFV600 -mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial. *Lancet Oncol.* May 2025; 26(5): 641-653. PMID 40250457
15. Ademuyiwa FO, Ma CX, Weilbaeher K, et al. Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer. *Clin Cancer Res.* Jun 03 2025; 31(11): 2173-2182. PMID 40116350
16. Yoo C, Jeong H, Jeong JH, et al. Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma. *J Hepatol.* May 2025; 82(5): 861-870. PMID 39532185
17. Taieb J, Souglakos J, Boukovinas I, et al. Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCORIDEA-France/HORG-IDEA-Greece Trials. *J Clin Oncol.* May 2025; 43(13): 1564-1577. PMID 39903903
18. Mayadev J, Vázquez Limón JC, Ramírez Godínez FJ, et al. Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses. *Ann Oncol.* Sep 2025; 36(9): 1047-1057. PMID 40500687
19. Long GV, Tang H, Desai K, et al. Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915. *J Immunother Cancer.* Jul 11 2025; 13(7). PMID 40645660
20. Azaïs H, Brochard C, Taly V, et al. Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial. *Gynecol Oncol.* Jan 2025; 192: 145-154. PMID 39671779
21. Shen T, Li T, Cao Y, et al. Circulating tumor DNA as a biomarker for progression and survival in esophageal cancer after neoadjuvant therapy and esophagectomy: a systematic review and meta-analysis. *Int J Surg.* Aug 12 2025; 111(11): 8515-22. PMID 40793951
22. Niu S, Sun T, Wang M, et al. Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: a meta-analysis. *BMC Cancer.* Jan 22 2025; 25(1):115. PMID 39844103
23. Zhang D, Jahanfar S, Rabinowitz JB, et al. Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis. *Breast Cancer Res.* Mar 12 2025; 27(1): 38. PMID 40075528
24. Leite da Silva LF, Saldanha EF, de Menezes JSA, et al. Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis. *Oncologist.* Feb 06 2025; 30(2). PMID 39998904
25. Kazemi-Harikandei SZ, Salmani Jelodar MR, Roshandel G, et al. The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis. *Biomark Med.* Aug 2025; 19(16): 793-806. PMID 40825939
26. Che S, Yu D. Predictive role of circulating tumor DNA based molecular residual disease for long-term outcomes in non-small cell lung cancer patients: a meta-analysis. *World J Surg Oncol.* Jun 13 2025; 23(1): 235. PMID 40514661
27. Zhang C, Zhao H, Shi Q. Postoperative Circulating Tumour DNA in Predicting Recurrence of Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis. *Clin Oncol (R Coll Radiol).* Aug 2025; 44:103892. PMID 40614309
28. Zhou Q, Chen X, Zeng B, et al. Circulating tumor DNA as a biomarker of prognosis prediction in colorectal cancer: a systematic review and meta-analysis. *J Natl Cancer Cent.* Apr 2025; 5(2): 167-178. PMID 40265088
29. Hoang T, Choi MK, Oh JH, et al. Utility of circulating tumor DNA to detect minimal residual disease in colorectal cancer: A systematic review and network meta-analysis. *Int J Cancer.* Aug 15 2025; 157(4):722-740. PMID 40293388

30. Holz A, Paul B, Zapf A, et al. Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis. *Cancer Treat Rev*. Sep 2025; 139: 102999. PMID 40743933
31. Negro S, Pulvirenti A, Trento C, et al. Circulating Tumor DNA as a Real-Time Biomarker for Minimal Residual Disease and Recurrence Prediction in Stage II Colorectal Cancer: A Systematic Review and Meta-Analysis. *Int J Mol Sci*. Mar 11 2025; 26(6). PMID 40141130
32. Fiorica F, Mandarà M, Giuliani J, et al. Circulating DNA in Rectal Cancer to Unravel the Prognostic Potential for Radiation Oncologist: A Meta-analysis. *Am J Clin Oncol*. Feb 01 2025; 48(2): 83-91. PMID39439084
33. Liu L, Hou S, Zhu A, et al. The prognostic value of circulating tumor DNA in malignant melanoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. *Front Immunol*. 2024; 15: 1520441. PMID 39896816
34. Noronha MM, da Silva LFL, Almeida LFC, et al. Prognostic and Predictive Value of ctDNA for Metastatic Uveal Melanoma: A Systematic Review and Meta-Analysis. *Pigment Cell Melanoma Res*. Sep 2025; 38(5): e70047. PMID 40799039
35. Zhao X, Hou S, Hao R, et al. Prognostic significance of circulating tumor DNA detection and quantification in cervical cancer: a systematic review and meta-analysis. *Front Oncol*. 2025; 15:1566750. PMID 40255423
36. Yang R, Li T, Zhang S, et al. The effect of circulating tumor DNA on the prognosis of patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis. *BMC Cancer*. Nov 212024; 24(1): 1434. PMID 39574043
37. Ma Q, Hou S, Ma H, et al. Prognostic significance of circulating tumor DNA in urothelial carcinoma patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis. *Front Immunol*. 2025; 16: 1574449. PMID 40364842
38. Gao X, Qi W, Li J, et al. Prognostic and predictive role of circulating tumor DNA detection in patients with muscle invasive bladder cancer: a systematic review and meta-analysis. *Cancer Cell Int*. Mar 012025; 25(1): 75. PMID 40025568
39. Zulfiqar A, Liliana B, Mataho NL, et al. The Use of Circulating Tumor Cells in T1 Stage Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. *Urol Res Pract*. Apr 04 2025; 50(6):343-350. PMID 40243380
40. Matheus GTFU, Ribeiro DM, Menegat ALRS, et al. Prognostic Significance of Circulating Tumor DNA Mutations in Gastrointestinal Stromal Tumors: A Systematic Review and Meta-analysis Based on Time-To-Event Data. *J Gastrointest Cancer*. Jul 15 2025; 56(1): 153. PMID 40665034
41. Sogbe M, Aliseda D, Sangro P, et al. Prognostic value of circulating tumor DNA in different cancer types detected by ultra-low-pass whole-genome sequencing: a systematic review and patient-level survival data meta-analysis. *Carcinogenesis*. Jan 20 2025; 46(1). PMID 39549302
42. Chiang AC, Madison RW, Assaf ZJ, et al. Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents. *JTO Clin Res Rep*. Sep 2025; 6(9): 100829. PMID 40746669
43. Mazel M, Jacot W, Pantel K, et al. Frequent expression of PD-L1 on circulating breast cancer cells. *Mol Oncol*. Nov 2015; 9(9): 1773-82. PMID 26093818
44. Lv Q, Gong L, Zhang T, et al. Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis. *Clin Transl Oncol*. Mar 2016; 18(3): 322-30. PMID 26260915
45. Wang CH, Chang CJ, Yeh KY, et al. The Prognostic Value of HER2-Positive Circulating Tumor Cells in Breast Cancer Patients: A Systematic Review and Meta-Analysis. *Clin Breast Cancer*. Aug 2017; 17(5):341-349. PMID 28347604
46. Zhang L, Riethdorf S, Wu G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. *Clin Cancer Res*. Oct 15 2012; 18(20): 5701-10. PMID 22908097
47. Huang X, Gao P, Song Y, et al. Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis. *BMC Cancer*. Dec 18 2014; 14:976. PMID 25519477
48. Groot Koerkamp B, Rahbari NN, Büchler MW, et al. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. *Ann Surg Oncol*. Jul 2013; 20(7): 2156-65. PMID 23456317

49. Fan JL, Yang YF, Yuan CH, et al. Circulating Tumor Cells for Predicting the Prognostic of Patients with Hepatocellular Carcinoma: A Meta Analysis. *Cell Physiol Biochem*. 2015; 37(2): 629-40. PMID26344495
50. Ma X, Xiao Z, Li X, et al. Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis. *Tumour Biol*. Jun 2014; 35(6):5551-60. PMID 24563278
51. Wang FB, Yang XQ, Yang S, et al. A higher number of circulating tumor cells (CTC) in peripheral blood indicates poor prognosis in prostate cancer patients--a meta-analysis. *Asian Pac J Cancer Prev*. 2011;12(10): 2629-35. PMID 22320965
52. de Bono J, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. *Clin Cancer Res*. 2008;14(19):6302-6309.PMID
53. Sun T, Zou K, Yuan Z, et al. Clinicopathological and prognostic significance of circulating tumor cells in patients with head and neck cancer: a meta-analysis. *Onco Targets Ther*. 2017; 10: 3907-3916. PMID28831265
54. Li Q, Ai L, Zuo L, et al. Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis. *Ann Med*. Dec 2024; 56(1): 2338604. PMID 38599340
55. Mocellin S, Hoon D, Ambrosi A, et al. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. *Clin Cancer Res*. Aug 01 2006; 12(15): 4605-13. PMID 16899608
56. Rack B, Schindlbeck C, Jückstock J, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. *J Natl Cancer Inst*. May 15 2014; 106(5). PMID 24832787
57. Thalgott M, Rack B, Horn T, et al. Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy. *Anticancer Res*. Oct2015; 35(10): 5679-85. PMID 26408743
58. Denève E, Riethdorf S, Ramos J, et al. Capture of viable circulating tumor cells in the liver of colorectal cancer patients. *Clin Chem*. Sep 2013; 59(9): 1384-92. PMID 23695297
59. Rink M, Chun FK, Dahlem R, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. *Eur Urol*. Apr 2012; 61(4):810-7. PMID 22277196
60. Gazzaniga P, de Berardinis E, Raimondi C, et al. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. *Int J Cancer*. Oct 15 2014; 135(8):1978-82. PMID 24599551
61. Schulze K, Gasch C, Staufer K, et al. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. *Int J Cancer*. Nov 2013; 133(9): 2165-71. PMID 23616258
62. Vashist YK, Effenberger KE, Vettorazzi E, et al. Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer. *Ann Surg*. Jun 2012; 255(6): 1105-12. PMID 22580852
63. Tie J, Cohen JD, Lahouel K, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. *N Engl J Med*. Jun 16 2022; 386(24): 2261-2272. PMID 35657320
64. Tie J, Wang Y, Lo SN, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. *Nat Med*. May 2025; 31(5): 1509-1518. PMID 40055522
65. Tie J, Wang Y, Loree JM, et al. ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG). *J. Clin. Oncol.*2025;43(16_suppl):3503, European Society for Medical Oncology (ESMO) Congress 2025, October 2025.
66. Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. *J Clin Oncol*. Nov 01 2014; 32(31): 3483-9. PMID 24888818
67. Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. *J Clin Oncol*. Apr 10 2022; 40(11): 1231-1258.PMID 35175857
68. Andre F, Ismaila N, Allison KH, et al. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. *J Clin Oncol*. Jun 01 2022; 40(16): 1816-1837. PMID35439025

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

